 Magenta Therapeutics Nasdaq: MGTA and the National Marrow Donor Program NMDPBe The Match, the global leader in providing a cure to patients with life-threatening blood and marrow cancers like leukemia, lymphoma and other diseases, today announced a clinical collaboration agreement to evaluate the potential utility of MGTA-145, Magentas investigational first-line stem cell mobilization program, for mobilizing and collecting hematopoietic stem cells from donors in a single day and then using them for allogeneic transplants in patients. This life-saving procedure is currently used in approximately 28,000 patients in the U.S. and Europe each year, but approximately 62,000 additional eligible patients do not receive an allogeneic transplant due to challenges, including difficulty with the donation process. 